Citigroup initiated coverage on BioNTech with a new price target
$BNTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citigroup initiated coverage of BioNTech with a rating of Buy and set a new price target of $145.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2025 | $134.00 → $145.00 | Buy | H.C. Wainwright |
| 5/29/2025 | $110.00 | Neutral | Goldman |
| 3/13/2025 | $145.00 | Buy | Citigroup |
| 1/10/2025 | $172.00 | Buy | Truist |
| 12/11/2024 | $170.00 | Overweight | Wells Fargo |
| 12/2/2024 | Outperform | BMO Capital Markets | |
| 11/19/2024 | $130.00 | Buy | Berenberg |
| 11/19/2024 | $110.00 → $125.00 | In-line → Outperform | Evercore ISI |